Heat shock protein 105 as an immunotherapeutic target for patients with cervical cancer

Kazuto Nosaka, Shiro Suzuki, Toshiaki Yoshikawa, Manami Shimomura, Kazuhisa Kitami, Kosuke Yoshida, Masato Yoshihara, Fumitaka Kikkawa, Tetsuya Nakatsura, Hiroaki Kajiyama

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Background/Aim: Heat shock protein 105 (HSP105) is overexpressed in various cancers, but not in normal tissues. We investigated the expression levels of HSP105 in cervical cancer and the efficacy of immunotherapy targeting HSP105. Materials and Methods: Previously, we established human leukocyte antigen-A∗02:01 (HLA-A2) restricted HSP105 peptide-specific cytotoxic T lymphocyte (CTL) clones from a colorectal cancer patient vaccinated with an HSP105 peptide. Herein, we evaluated the expression of HSP105 in cervical cancer and cervical intraepithelial neoplasia. Moreover, we tested the effectiveness of an HLAA2-restricted HSP105 peptide-specific CTL clone against cervical cancer cell lines. Results: HSP105 was expressed in 95% (19/20) of examined cervical cancer tissues. Moreover, the HSP105 peptide-specific CTL clone recognized HSP105- and HLA-A∗02:01-positive cervical cancer cell lines and also showed that cytotoxicity against the cervical cancer cell lines depends on HSP105 peptide and HLA class I restricted manners. Conclusion: HSP105 could be an effective target for immunotherapy in patients with cervical cancer.

Original languageEnglish
Pages (from-to)4741-4751
Number of pages11
JournalAnticancer research
Issue number10
Publication statusPublished - 2021 Oct
Externally publishedYes


  • Cancer germline antigen
  • Cancer immunotherapy
  • Cervical cancer
  • Cytotoxic T lymphocyte clone
  • Heat shock protein 105

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Heat shock protein 105 as an immunotherapeutic target for patients with cervical cancer'. Together they form a unique fingerprint.

Cite this